Search

Your search keyword '"Weickert, Martin O."' showing total 549 results
Start Over Author "Weickert, Martin O."
549 results on '"Weickert, Martin O."'

4. IGF-1 and IGFBP-1 as Possible Predictors of Response to Lifestyle Intervention—Results from Randomized Controlled Trials

Author

Meyer, Nina M. T., primary, Kabisch, Stefan, additional, Dambeck, Ulrike, additional, Honsek, Caroline, additional, Kemper, Margrit, additional, Gerbracht, Christiana, additional, Arafat, Ayman M., additional, Birkenfeld, Andreas L., additional, Schwarz, Peter E. H., additional, Machann, Jürgen, additional, Osterhoff, Martin A., additional, Weickert, Martin O., additional, and Pfeiffer, Andreas F. H., additional

Published
2024
Full Text
View/download PDF

5. IGF-1 and IGFBP-1, Possible Predictors of Response to Lifestyle Intervention – Results from Randomized Controlled Trials

Author

Meyer, Nina M.T., primary, Kabisch, Stefan, additional, Dambeck, Ulrike, additional, Honsek, Caroline, additional, Kemper, Margrit, additional, Gerbracht, Christiana, additional, Arafat, Ayman M., additional, Birkenfeld, Andreas L., additional, Schwarz, Peter E. H., additional, Machann, Jürgen, additional, Osterhoff, Martin A., additional, Weickert, Martin O., additional, and Pfeiffer, Andreas F. H., additional

Published
2024
Full Text
View/download PDF

8. Dietary and Lifestyle Strategies for Obesity.

Author

Barber, Thomas M., Kabisch, Stefan, Pfeiffer, Andreas F. H., and Weickert, Martin O.

Abstract

The prevalence of obesity globally has tripled over the last half century, and currently affects around 650 million adults and 340 million children and adolescents (ages 5–19 years). Obesity contributes towards >50 co-morbidities and premature mortality. Obesity is a highly stigmatised condition that is associated with much mental and emotional distress and dysfunction. Thus, obesity is a major contributor to healthcare expenditure globally. Traditionally, the management of obesity stratifies into three major groups that include metabolic (bariatric) surgery, pharmacotherapies, and lifestyle (primarily dietary) strategies. Although listed as a separate category, dietary strategies for obesity remain a central component of any management plan, and often complement other surgical and pharmacotherapeutic options. Indeed, the effectiveness of any management approach for obesity relies upon successful behavioural changes, particularly relating to eating behaviours. In this concise review, we explore the foundational pillars of dietary strategies for obesity: sleep, listening, routine, de-stressing and optimisation of social conditions. We then discuss the importance of balancing dietary macronutrients (including dietary fibre, carbohydrates, protein and ultra-processed foods [UPFs]) as a key dietary strategy for obesity. Although we focus on general principles, we should provide bespoke dietary strategies for our patients, tailored to their individual needs. Rather than judging the utility of a diet based simply on its associated magnitude of weight loss, we should adopt a more holistic perspective in which a dietary strategy is valued for its overall health benefits, including the nurturing of our gut microbiota, to enable them to nurture and protect us. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Contributors

Author

Abbott, David H., primary, Altieri, Paola, additional, Anagnostis, Panagiotis, additional, Antoniou-Tsigkos, Athanasios, additional, Armeni, Eleni, additional, Balen, Adam H., additional, Barber, Thomas M., additional, Benvenga, Salvatore, additional, Carmina, Enrico, additional, Cecchetti, Carolina, additional, Crisosto, Nicolás, additional, Di Bari, Flavia, additional, Diamanti-Kandarakis, Evanthia, additional, Dinicola, Simona, additional, Escobar-Morreale, Héctor F., additional, Fanelli, Flaminia, additional, Fighera, T.M., additional, Forte, Gianpiero, additional, Gambineri, Alessandra, additional, Georgescu, Carmen Emanuela, additional, Georgopoulos, Neoklis A., additional, Goulis, Dimitrios G., additional, Greinwald, Emily P., additional, Kahal, Hassan, additional, Kandaraki, Eleni, additional, Kyrou, Ioannis, additional, Lambrinoudaki, Irene, additional, Lecke, S.B., additional, Levine, Jon E., additional, Marchesan, L.B., additional, Markantes, Georgios K., additional, Mascarenhas, Mariano, additional, Mastorakos, George, additional, Memi, Eleni, additional, Moghetti, Paolo, additional, Monastra, Giovanni, additional, Oguz, Seda Hanife, additional, Pagotto, Uberto, additional, Papadimitriou, Kasiani, additional, Papalou, Olga, additional, Pastroma, Konstantina, additional, Pereira, Sofia S., additional, Pignatelli, Duarte, additional, Preiato, Valentina Lo, additional, Randeva, Harpal S., additional, Ribichini, Danilo, additional, Santos, B.R., additional, Sendur, Suleyman Nahit, additional, Spritzer, P.M., additional, Tilotta, Marco, additional, Tsichlia, Gina, additional, Unfer, Vittorio, additional, Unluturk, Ugur, additional, Vrachnis, Nikolaos, additional, Weickert, Martin O., additional, and Yildiz, Bulent Okan, additional

Published
2022
Full Text
View/download PDF

15. The role of cereal soluble fiber in the beneficial modulation of glycometabolic gastrointestinal hormones.

Author

Kabisch, Stefan, Weickert, Martin O., and Pfeiffer, Andreas F. H.

Subjects
*GLYCOCALYX, *GASTROINTESTINAL hormones, *SHORT-chain fatty acids, *FATTY liver, *TYPE 2 diabetes, *INSULIN resistance
Abstract

According to cohort studies, cereal fiber, and whole-grain products might decrease risk for type 2 diabetes (T2DM), inflammatory processes, cancer, and cardiovascular diseases. These associations, mainly affect insoluble, but not soluble cereal fiber. In intervention studies, soluble fiber elicit anti-hyperglycemic and anti-inflammatory short-term effects, partially explained by fermentation to short-chain fatty acids, which acutely counteract insulin resistance and inflammation. ß-glucans lower cholesterol levels and possibly reduce liver fat. Long-term benefits are not yet shown, maybe caused by T2DM heterogeneity, as insulin resistance and fatty liver disease – the glycometabolic points of action of soluble cereal fiber – are not present in every patient. Thus, only some patients might be susceptive to fiber. Also, incretin action in response to fiber could be a relevant factor for variable effects. Thus, this review aims to summarize the current knowledge from human studies on the impact of soluble cereal fiber on glycometabolic gastrointestinal hormones. Effects on GLP-1 appear to be highly contradictory, while these fibers might lower GIP and ghrelin, and increase PYY and CCK. Even though previous results of specific trials support a glycometabolic benefit of soluble fiber, larger acute, and long-term mechanistic studies are needed in order to corroborate the results. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. The global leadership into malnutrition criteria reveals a high percentage of malnutrition which influences overall survival in patients with gastroenteropancreatic neuroendocrine tumours.

Author

Clement, Dominique S. V. M., van Leerdam, Monique E., Tesselaar, Margot E. T., Cananea, Elmie, Martin, Wendy, Weickert, Martin O., Sarker, Debashis, Ramage, John K., and Srirajaskanthan, Rajaventhan

Subjects
NEUROENDOCRINE tumors, OVERALL survival, MALNUTRITION, BODY mass index, BODY composition
Abstract

Patients with neuroendocrine tumours located in the gastroenteropancreatic tract (GEP‐NETs) and treatment with somatostatin analogues (SSA's) are at risk of malnutrition which has been reported previously evaluating weight loss or body mass index (BMI) only. The global leadership into malnutrition (GLIM) criteria include weight loss, BMI, and sarcopenia, for diagnosing malnutrition. These GLIM criteria have not been assessed in patients with GEP‐NETs on SSA. The effect of malnutrition on overall survival has not been explored before. The aim of this study is to describe the presence of malnutrition in patients with GEP‐NET on SSA based on the GLIM criteria and associate this with overall survival. Cross‐sectional study screening all patients with GEP‐NETs on SSA's for malnutrition using the GLIM criteria. Body composition analysis for sarcopenia diagnosis were performed. Bloods including vitamins, minerals, and lipid profile were collected. Overall survival since the date of nutrition screening was calculated. Uni‐ and multivariate Cox regression analysis were performed to identify malnutrition as risk factor for overall survival. A total of 118 patients, 47% male, with median age 67 years (IQR 56.8–75.0) were included. Overall, malnutrition was present in 88 patients (75%); based on low BMI in 26 (22%) patients, based on weight loss in 35 (30%) patients, and based on sarcopenia in 83 (70%) patients. Vitamin deficiencies were present for vitamin D in 64 patients (54%), and vitamin A in 29 patients (25%). The presence of malnutrition demonstrated a significantly worse overall survival (p‐value =.01). In multivariate analysis meeting 2 or 3 GLIM criteria was significantly associated with worse overall survival (HR 2.16 95% CI 1.34–3.48, p‐value =.002). Weight loss was the most important risk factor out of the 3 GLIM criteria (HR 3.5 95% CI 1.14–10.85, p‐value =.03) for worse overall survival. A high percentage (75%) of patients with GEP‐NETs using a SSA meet the GLIM criteria for malnutrition. Meeting more than 1 GLIM criterium, especially if there is weight loss these are risk factors for worse overall survival. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Rising arterial stiffness with accumulating comorbidities associates with heart failure with preserved ejection fraction

Author

Ali, Danish, primary, Tran, Patrick, additional, Ennis, Stuart, additional, Powell, Richard, additional, McGuire, Scott, additional, McGregor, Gordon, additional, Kimani, Peter K., additional, Weickert, Martin O., additional, Miller, Michelle A., additional, Cappuccio, Francesco P., additional, and Banerjee, Prithwish, additional

Published
2023
Full Text
View/download PDF

24. Pancreatic metastases in patients with neuroendocrine neoplasms: A multi‐centre cohort study

Author

Tsoli, Marina, primary, Daskalakis, Kosmas, additional, Wedin, Maria, additional, Angelousi, Anna, additional, Povlsen, Sebastian, additional, Srirajaskanthan, Raj, additional, Giovos, George, additional, Weickert, Martin O., additional, Kogut, Angelika, additional, Kos‐Kudla, Beata, additional, Oleinikov, Kira, additional, Grozinsky‐Glasberg, Simona, additional, and Kaltsas, Gregory, additional

Published
2023
Full Text
View/download PDF

26. Assessment of circulating Wnt1 inducible signalling pathway protein 1 (WISP-1)/CCN4 as a novel biomarker of obesity

Author

Tacke, Christopher, Aleksandrova, Krasimira, Rehfeldt, Miriam, Murahovschi, Veronica, Markova, Mariya, Kemper, Margrit, Hornemann, Silke, Kaiser, Ulrike, Honig, Caroline, Gerbracht, Christiana, Kabisch, Stefan, Hörbelt, Tina, Ouwens, D. Margriet, Weickert, Martin O., Boeing, Heiner, Pfeiffer, Andreas F. H., Pivovarova, Olga, and Rudovich, Natalia

Published
2018
Full Text
View/download PDF

33. Predicting Factors for Metabolic Non-Response to a Complex Lifestyle Intervention—A Replication Analysis to a Randomized-Controlled Trial

Author

Kabisch, Stefan, primary, Meyer, Nina M. T., additional, Honsek, Caroline, additional, Kemper, Margrit, additional, Gerbracht, Christiana, additional, Arafat, Ayman M., additional, Dambeck, Ulrike, additional, Osterhoff, Martin A., additional, Weickert, Martin O., additional, and Pfeiffer, Andreas F. H., additional

Published
2022
Full Text
View/download PDF

34. Association of lymph node metastases, grade and extent of mesenteric lymph node dissection in locoregional small intestinal neuroendocrine tumors with recurrence‐free survival

Author

Daskalakis, Kosmas, primary, Wedin, Maria, additional, Tsoli, Marina, additional, Kogut, Angelika, additional, Srirajaskanthan, Raj, additional, Sarras, Konstantinos, additional, Kattiparambil, Sajith, additional, Giovos, George, additional, Weickert, Martin O., additional, Kos‐Kudla, Beata, additional, and Kaltsas, Gregory, additional

Published
2022
Full Text
View/download PDF

36. The DAPA‐DIET study: Metabolic response to Dapagliflozin combined with dietary carbohydrate restriction in patients with Type 2 Diabetes Mellitus and Obesity—A longitudinal cohort study

Author

Hanson, Petra, primary, Randeva, Harpal, additional, Cuthbertson, Dan J., additional, O'Hare, Paul J., additional, Parsons, Nick, additional, Chatha, Kamaljit, additional, Reidy, Gemma, additional, Weickert, Martin O., additional, and Barber, Thomas M., additional

Published
2022
Full Text
View/download PDF

37. Low IGF1 and high IGFBP1 predict diabetes onset in prediabetic patients

Author

Meyer, Nina M T, primary, Kabisch, Stefan, additional, Dambeck, Ulrike, additional, Honsek, Caroline, additional, Kemper, Margrit, additional, Gerbracht, Christiana, additional, Arafat, Ayman M, additional, Birkenfeld, Andreas L, additional, Schwarz, Peter E H, additional, Machann, Jürgen, additional, Osterhoff, Martin A, additional, Weickert, Martin O, additional, and Pfeiffer, Andreas F H, additional

Published
2022
Full Text
View/download PDF

38. Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm: interim analysis of prospective ASPEN trial

Author

Partelli, Stefano, primary, Massironi, Sara, additional, Zerbi, Alessandro, additional, Niccoli, Patricia, additional, Kwon, Wooil, additional, Landoni, Luca, additional, Panzuto, Francesco, additional, Tomazic, Ales, additional, Bongiovanni, Alberto, additional, Kaltsas, Gregory, additional, Sauvanet, Alain, additional, Bertani, Emilio, additional, Mazzaferro, Vincenzo, additional, Caplin, Martyn, additional, Armstrong, Thomas, additional, Weickert, Martin O, additional, Ramage, John, additional, Segelov, Eva, additional, Butturini, Giovanni, additional, Staettner, Stefan, additional, Cives, Mauro, additional, Frilling, Andrea, additional, Moulton, Carol Anne, additional, He, Jin, additional, Boesch, Florian, additional, Selberheer, Andreas, additional, Twito, Orit, additional, Castaldi, Antonio, additional, De Angelis, Claudio G, additional, Gaujoux, Sebastien, additional, Holzer, Katharina, additional, Wilson, Colin H, additional, Almeamar, Hussein, additional, Vigia, Emanuel, additional, Muffatti, Francesca, additional, Lucà, Martina, additional, Lania, Andrea, additional, Ewald, Jacques, additional, Kim, Hongbeom, additional, Salvia, Roberto, additional, Rinzivillo, Maria, additional, Smid, Alojz, additional, Gardini, Andrea, additional, Tsoli, Marina, additional, Hentic, Olivia, additional, Colombo, Samuele, additional, Citterio, Davide, additional, Toumpanakis, Christos, additional, Ramsey, Emma, additional, Randeva, Harpal S, additional, Srirajaskanthan, Ray, additional, Croagh, Daniel, additional, Regi, Paolo, additional, Gasteiger, Silvia, additional, Invernizzi, Pietro, additional, Ridolfi, Cristina, additional, Giovannini, Marc, additional, Jang, Jin-Young, additional, Bassi, Claudio, additional, and Falconi, Massimo, additional

Published
2022
Full Text
View/download PDF

43. Compliance bei komplexer Lebensstilintervention – eine differenzierte Auswertung der PREDIAS-Intervention im Rahmen der OptiFiT-Studie (Optimal Fiber Trial)

Author

Sachno, Anna, additional, Kabisch, Stefan, additional, Honsek, Caroline, additional, Gerbracht, Christiana, additional, Kemper, Margrit, additional, Dambeck, Ulrike, additional, Osterhoff, Martin, additional, Birkenfeld, Andreas L., additional, Arafat, Ayman M., additional, Weickert, Martin O., additional, Spranger, Joachim, additional, and Pfeiffer, Andreas F.H., additional

Published
2022
Full Text
View/download PDF

48. Effects of supplemented isoenergetic diets differing in cereal fiber and protein content on insulin sensitivity in overweight humans

Author

Weickert, Martin O, Roden, Michael, Isken, Frank, Hoffmann, Daniela, Nowotny, Peter, Osterhoff, Martin, Blaut, Michael, Alpert, Carl, Gögebakan, Özlem, Bumke-Vogt, Christiane, Mueller, Friederike, Machann, Jürgen, Barber, Tom M, Petzke, Klaus J, Hierholzer, Johannes, Hornemann, Silke, Kruse, Michael, Illner, Anne-Kathrin, Kohl, Angela, Loeffelholz, Christian V, Arafat, Ayman M, Möhlig, Matthias, and Pfeiffer, Andreas FH

Published
2011
Full Text
View/download PDF

50. Asprosin, a novel pleiotropic adipokine implicated in fasting and obesity-related cardio-metabolic disease:Comprehensive review of preclinical and clinical evidence

Author

Shabir, Kiran, Brown, James E., Afzal, Islam, Gharanei, Seley, Weickert, Martin O., Barber, Thomas M., Kyrou, Ioannis, and Randeva, Harpal S.

Abstract

White adipose tissue is a dynamic endocrine organ that releases an array of adipokines, which play a key role in regulating metabolic homeostasis and multiple other physiological processes. An altered adipokine secretion profile from adipose tissue depots frequently characterizes obesity and related cardio-metabolic diseases. Asprosin is a recently discovered adipokine that is released in response to fasting. Following secretion, asprosin acts - via an olfactory G-protein coupled receptor and potentially via other unknown receptor(s) - on hepatocytes and agouti-related peptide-expressing neurons in the central nervous system to stimulate glucose secretion and promote appetite, respectively. A growing body of both in vitro and in vivo studies have shown asprosin to exert a number of effects on different metabolic tissues. Indeed, asprosin can attenuate insulin signalling and promote insulin resistance in skeletal muscle by increasing inflammation and endoplasmic reticulum stress. Interestingly, asprosin may also play a protective role in cardiomyocytes that are exposed to hypoxic conditions. Moreover, clinical studies have reported elevated circulating asprosin levels in obesity, type 2 diabetes and other obesity-related cardio-metabolic diseases, with significant associations to clinically relevant parameters. Understanding the spectrum of the effects of this novel adipokine is essential in order to determine its physiologic role and its significance as a potential therapeutic target and/or a biomarker of cardio-metabolic disease. The present review offers a comprehensive overview of the published literature on asprosin, including both clinical and preclinical studies, focusing on its role in metabolism and cardio-metabolic disease.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results